The future of Nippon Shinyaku’s Duchenne muscular dystrophy (DMD) therapy Viltepso has been thrown into doubt after it failed a clinical trial designed to upgrade its 2020 accelerated approval. The ...

The FDA has placed another clinical hold on a gene therapy for Duchenne muscular dystrophy developed by Solid Biosciences, pulverising its share price. The halt of the IGNITE DMD trial was prompted by ...

Dyne Therapeutics is advancing its investigational exon-skipping therapy zeleciment rostudirsen (z-rostudirsen), formerly known as DYNE-251, toward regulatory approval after trial data showed early ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google The latest Phase 3 trial results continue showing that deramiocel ...

Exceptionally qualified high school seniors who plan to pursue careers in dentistry are offered places each year in the Pre-Professional Scholars Program in dentistry. Participants in this 3+4 program ...

Cardiomyopathy is the leading cause of death in boys with Duchenne muscular dystrophy (DMD). While cardiac magnetic resonance (CMR) is routinely used to assess fibrosis and left ventricular (LV) ...

Explore the complete Investing.com Diamond Index historical data, offering detailed insights into daily prices, including open, high, low, volume, and percentage changes. Use this data to analyze long ...

PHOENIX — Jace Taylor is a rambunctious 4-year-old boy. He runs, jumps and plays with his friends. He isn’t aware that genetically, he’s different from other children. “I think he’s too young to ...